Mohammed Ahmed1, Antoinette Flannery1, Cyrus Daneshvar2, David Breen1. 1. Interventional Respiratory Unit, Galway University Hospital, Galway, Ireland. 2. Department of Respiratory Medicine, Plymouth Hospitals NHS Trust, Plymouth, United Kingdom.
Abstract
BACKGROUND: Cervical lymph nodes are frequently involved in patients with lung cancer and indicate inoperability. Some guidelines recommend neck ultrasound (NUS) in patients with bulky mediastinal lymphadenopathy. Positron emission tomography (PET) is indicated for patients with potentially curable disease. OBJECTIVES: We aimed to assess the diagnostic yield of NUS and the diagnostic accuracy of PET for cervical lymphadenopathy in this group with a high pre-test probability of N3 disease. METHODS: Records of all patients with lung cancer who underwent an NUS over a consecutive 5-year period were reviewed. Only patients with mediastinal lymphadenopathy on computerised tomography (CT) were included. The diagnostic accuracy of PET was assessed with NUS-guided fine needle aspiration cytology used as the reference test. RESULTS: During the study period, 123 patients met the inclusion criteria. Malignant cervical lymphadenopathy was confirmed in 49/123 (39.8% [95% CI 31.1-49.1]). PET-CT had a specificity of 81.1%, sensitivity of 87.5%, negative predictive value of 96.8% and positive predictive value of 50% for the detection of cervical lymphadenopathy, and it contributed no additional staging information in the neck area. Overall, PET led to a change in management in only 2.2% of cases. CONCLUSION: A significant proportion of patients with lung cancer and mediastinal lymphadenopathy have cervical lymphadenopathy detected by NUS. In this group of patients, PET offers minimal additional value in staging and management.
BACKGROUND: Cervical lymph nodes are frequently involved in patients with lung cancer and indicate inoperability. Some guidelines recommend neck ultrasound (NUS) in patients with bulky mediastinal lymphadenopathy. Positron emission tomography (PET) is indicated for patients with potentially curable disease. OBJECTIVES: We aimed to assess the diagnostic yield of NUS and the diagnostic accuracy of PET for cervical lymphadenopathy in this group with a high pre-test probability of N3 disease. METHODS: Records of all patients with lung cancer who underwent an NUS over a consecutive 5-year period were reviewed. Only patients with mediastinal lymphadenopathy on computerised tomography (CT) were included. The diagnostic accuracy of PET was assessed with NUS-guided fine needle aspiration cytology used as the reference test. RESULTS: During the study period, 123 patients met the inclusion criteria. Malignant cervical lymphadenopathy was confirmed in 49/123 (39.8% [95% CI 31.1-49.1]). PET-CT had a specificity of 81.1%, sensitivity of 87.5%, negative predictive value of 96.8% and positive predictive value of 50% for the detection of cervical lymphadenopathy, and it contributed no additional staging information in the neck area. Overall, PET led to a change in management in only 2.2% of cases. CONCLUSION: A significant proportion of patients with lung cancer and mediastinal lymphadenopathy have cervical lymphadenopathy detected by NUS. In this group of patients, PET offers minimal additional value in staging and management.
Authors: Benjamin C Creelan; Chao Wang; Eric B Haura; Scott J Antonia; Jamie K Teer; Eric M Toloza; Jiqiang Yao; Sungjune Kim; Ana M Landin; John E Mullinax; James J Saller; Andreas N Saltos; David R Noyes; Leighann B Montoya; Wesley Curry; Shari A Pilon-Thomas; Alberto A Chiappori; Tawee Tanvetyanon; Frederic J Kaye; Zachary J Thompson; Sean J Yoder; Bin Fang; John M Koomen; Amod A Sarnaik; Dung-Tsa Chen; Jose R Conejo-Garcia Journal: Nat Med Date: 2021-08-12 Impact factor: 87.241